RESUMEN
BACKGROUND: Our objective was to determine if cholecystectomy for biliary dyskinesia (BD) was performed more commonly in the United States than in 4 comparator countries around the world. METHODS: Using the Nationwide Inpatient Sample, we extracted and analyzed data for cholecystectomy from 1991 to 2011 using ICD-9 (International Classification of Diseases 9th Revision) procedure codes. To derive the number of cholecystectomies performed for BD, we used the ICD-9 code 575.8, greater than 80% of which are patients with BD. The same or equivalent code was used for the international comparator group. Through a SURGINET query we obtained data from verifiable national databases in 4 developed countries including the Swedish quality registry for surgical treatments of gallstone-related conditions (GallRiks), the Norwegian Cholecystectomy Registry, the Australian Bureau of Statistics, and the Polish National Health Insurance Agency. RESULTS: In the years ranging from 2008 to 2011, the number of cholecystectomies for BD per 1,000,000 population per year was less than 25 in the 4 comparator countries and greater than 85 in the United States (P < .01). From 1991 to 2011, the number of cholecystectomies for BD in the United States significantly increased from 43.3 to 89.1 per 1,000,000 population (P < .01). CONCLUSIONS: These data strongly suggest that cholecystectomy for BD is over utilized in the United States. In addition, this trend continues to increase in frequency.
Asunto(s)
Discinesia Biliar/epidemiología , Sistema de Registros , Discinesia Biliar/diagnóstico , Discinesia Biliar/cirugía , Colecistectomía/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Salud Global , Humanos , Incidencia , Masculino , Prevalencia , Estudios Retrospectivos , Estados Unidos/epidemiologíaAsunto(s)
Antibacterianos/administración & dosificación , Apendicitis/tratamiento farmacológico , Ciprofloxacina/administración & dosificación , Metronidazol/administración & dosificación , Ácido Penicilánico/análogos & derivados , Piperacilina/administración & dosificación , Femenino , Humanos , Masculino , Ácido Penicilánico/administración & dosificación , TazobactamAsunto(s)
Úlcera Duodenal/cirugía , Gastroenterostomía/efectos adversos , Gastroenterostomía/métodos , Úlcera Péptica Hemorrágica/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Duodeno/cirugía , Femenino , Gastroenterostomía/mortalidad , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Antro Pilórico/cirugía , Resultado del Tratamiento , VagotomíaAsunto(s)
Fístula Cutánea/terapia , Procedimientos Quirúrgicos del Sistema Digestivo/efectos adversos , Fístula Intestinal/terapia , Cuidados Posoperatorios , Fístula Cutánea/etiología , Fístula Cutánea/mortalidad , Humanos , Fístula Intestinal/etiología , Fístula Intestinal/mortalidad , Cuidados Posoperatorios/instrumentación , Cuidados Posoperatorios/métodosAsunto(s)
Apendicitis/cirugía , Colecistitis/cirugía , Procedimientos Quirúrgicos del Sistema Digestivo , Drenaje/estadística & datos numéricos , Úlcera Péptica Perforada/cirugía , Peritonitis/cirugía , Humanos , Cuidados Posoperatorios , Pautas de la Práctica en Medicina/estadística & datos numéricosRESUMEN
BACKGROUND: We aimed to improve the postoperative outcome of high-risk patients (American Society of Anesthesiologists class 3 and 4) recovering from colorectal cancer surgery by using recombinant human G-CSF (filgrastim) as perioperative prophylaxis. METHODS: In a double-blinded, placebo-controlled trial, 80 patients undergoing left-sided colorectal resection were randomized to filgrastim or placebo. Filgrastim (5 mug/kg) or placebo was administered in the afternoon on day -1, 0, and +1 relative to the operation. Primary endpoints were in a hierarchic order: quality of life (QoL) over time (determined at discharge, 2 and 6 months after operation with the European Organization for Research and Treatment of Cancer questionnaire) and the McPeek recovery score, which measures death and duration of stays in the intensive care unit and hospital. Predefined secondary endpoints were global QoL, subdomains of QoL, postoperative recovery, duration of stay, 6-month overall survival, complication rates, and cellular and immunologic parameters. RESULTS: There were no significant differences in both primary endpoints between the treatment groups. A significant improvement (P < .05) was obtained by filgrastim prophylaxis in the QoL subdomain family life /- social functioning,; thus, more patients recovered to their preoperative state (14 vs 4 with placebo) as determined by structured interviews. Duration of hospital stay (14 vs 12 days) and noninfectious complications were decreased from 8% to 3%. CONCLUSIONS: High-risk patients undergoing major operation for colorectal cancer profited from filgrastim prophylaxis with regard to duration of hospital stay, noninfectious complications, social QoL, and subjective recovery from operation. These endpoints, however, were secondary, and the primary endpoints (overall QoL and the McPeek index) did not show comparable benefits. A new confirmatory trial with the successful endpoints of this trial, as well as a cost analysis, will be needed to confirm the results before a general recommendation for the prophylactic use of G-CSF in high-risk cancer patients can be given.
Asunto(s)
Adenocarcinoma/cirugía , Neoplasias Colorrectales/cirugía , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Fármacos Hematológicos/uso terapéutico , Complicaciones Posoperatorias/prevención & control , Anciano , Anciano de 80 o más Años , Colectomía , Método Doble Ciego , Femenino , Filgrastim , Humanos , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Atención Perioperativa/métodos , Proteínas RecombinantesRESUMEN
The AMA Guidelines for Adolescent Preventive Services (GAPS) has been the cornerstone of preventive care for teenagers since its publication in 1994. Despite this, there has been little documentation of their implementation in the family medicine literature. This article gives an overview of a family practice-based adolescent preventive health program based on GAPS recommendations, and reports on compliance, feasibility and health issues. A Community-Oriented Primary Care (COPC) program targeted all adolescent patients aged 12-18 years in two Israeli family practices. 321 teenagers were invited to participate. Every 7th and 10th grader was invited for a preventive health visit with the family physician and nurse. The visits included a medical evaluation, screening and counseling regarding health issues recommended by GAPS, and counseling regarding personal health concerns. Parents were also invited to meet with the staff. 184 (57%) of the adolescents invited for health visits attended. The overall visit time was 47 minutes, including 12 minutes for a questionnaire and 35 minutes with providers. Common biomedical problems included overweight, acne and dysmenorrhea. Health risk behaviors and psychosocial problems included cigarette or alcohol use, dieting, infrequent/never seat belt use, and feeling depressed. 78% wanted to discuss at least one personal health issue. 27% were invited for follow-up visits. Only 3% of the parents came for visits. A community-oriented approach facilitates bringing adolescents for preventive health visits. Many previously undetected health issues, particularly psychosocial and behavioral, are revealed during these visits. A concerns checklist aids in addressing personal health concerns.
Asunto(s)
Servicios de Salud del Adolescente/normas , Medicina Familiar y Comunitaria/normas , Servicios Preventivos de Salud/estadística & datos numéricos , Acné Vulgar/terapia , Adolescente , Servicios de Salud del Adolescente/estadística & datos numéricos , Dismenorrea/terapia , Femenino , Indicadores de Salud , Humanos , Israel , Masculino , Tamizaje Masivo , Obesidad/terapia , Aceptación de la Atención de Salud , Guías de Práctica Clínica como Asunto , Servicios Preventivos de Salud/normas , Asunción de RiesgosRESUMEN
Urachal remnant disorders are uncommon and may cause a wide spectrum of manifestations. We report a case of an inflamed urachal cyst causing acute small bowel obstruction in a 44-year-old male patient. The relevant literature is reviewed.